USPTO serial 99058243
GREENWICH BIOSCIENCES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 18, 2025
- Examiner
- PHILLIPS, ALEXANDER J
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with GREENWICH BIOSCIENCES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Jazz Pharmaceuticals Operations UK Limited
Kent, GB
Other trademarks owned by Jazz Pharmaceuticals Operations UK Limited
Jazz Pharmaceuticals Operations UK Limited
Kent, GB
Other trademarks owned by Jazz Pharmaceuticals Operations UK Limited
Jazz Pharmaceuticals Operations UK Limited
Kent, GB
Other trademarks owned by Jazz Pharmaceuticals Operations UK Limited
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michael T. Olsen
Michael T. Olsen Winthrop & Weinstine, P.A.225 South 6th Street, Suite 3500Minneapolis, MN 55402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for the treatment of pain, neuropathic pain, cancer pain, perioperative pain, cancer symptoms, multiple sclerosis (MS), spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalised epilepsy with febrile seizures plus (GEFS positive), dup 15, and Doose syndrome, and for use in oncology; pharmaceutical preparations and substances for the treatment of bladder dysfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, LennoxGastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory disorders, inflammation, arthritis; pharmaceutical preparations and substances for the treatment of metabolic disorders, cancer symptoms, neurodegenerative diseases, diseases of the central nervous system, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness and chemically induced sickness and for the use in oncology; pharmaceutical preparations and substances for the treatment of diabetes, type II diabetes, obesity, obesity associated with diabetes, bulimia, psychiatric disorders, schizophrenia, and drug, alcohol and nicotine abuse, autism; herbs for medicinal purposes; medicinal herbs; medicinal infusions for treating pain, neuropathic pain, cancer pain, peri-operative pain, cancer symptoms, multiple sclerosis, spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC), generalised epilepsy with febrile seizures plus (GEFS positive), dup 15, and Doose syndrome and for use in oncology; medicinal infusions for treating bladder dysfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, LennoxGastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory disorders, inflammation, arthritis; medicinal infusions for treating metabolic disorders, cancer symptoms, neurodegenerative diseases, diseases of the central nervous system, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness and chemically induced sickness and for use in oncology; medicinal infusions for treating diabetes, type II diabetes, obesity, obesity associated with diabetes, bulimia, psychiatric disorders, schizophrenia, and drug, alcohol and nicotine abuse, autism; pure extracts of medicinal plants and herbs other than essential oils for medical, veterinary and pharmaceutical purposes; foodstuffs for medicinal purposes, namely, medicated supplements for foodstuffs for babies and animals; herb teas for medicinal purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Jazz Pharmaceuticals Operations UK Limited
- Other trademarks owned by Jazz Pharmaceuticals Operations UK Limited
- Other trademarks owned by Jazz Pharmaceuticals Operations UK Limited
- Other trademarks in Class 005
- Similar marks named GREENWICH BIOSCIENCES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 18, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 18, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 30, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 30, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 24, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 2, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 29, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 29, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 29, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 8, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 8, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 8, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 31, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 26, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 26, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 26, 2025 | NWAP | NEW APPLICATION ENTERED | — |